Dupont Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Dupont Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,530	Closed	-$78.1K	–	991
2022 Q4	$78.1K	Buy	+1,530	New	+$106K	﹤0.01%	997
2022 Q3	–	Sell	-2,430	Closed	-$164K	–	1622
2022 Q2	$164K	Buy	2,430 +915	+60%	+$83.9K	0.01%	1031
2022 Q1	$167K	Sell	1,515 -1,978	-57%	-$247K	0.01%	1124
2021 Q4	$337K	Sell	3,493 -1,393	-29%	-$139K	0.01%	939
2021 Q3	$427K	Buy	+4,886	New	+$507K	0.01%	955

Other funds holding KPTI

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dupont Capital Management's KPTI Position: Q1 2023 in Review

Dupont Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2023, closing a stake of 1,530 shares — an estimated $78.1K sold.

Dupont Capital Management first reported a position in KPTI in Q3 2021 and held it in 5 quarters. The position peaked at $427K in Q3 2021. 129 funds tracked by Wall St. Rank hold KPTI as of Q1 2023.

Dupont Capital Management reported no remaining Karyopharm Therapeutics position as of Q1 2023 after selling out during the quarter.
Dupont Capital Management sold 1,530 Karyopharm Therapeutics shares in Q1 2023, an estimated $78.1K.
Dupont Capital Management first reported a position in Karyopharm Therapeutics in Q3 2021 and held it in 5 quarters.
Dupont Capital Management's Karyopharm Therapeutics position peaked at $427K in Q3 2021.
129 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2023.

Based on Dupont Capital Management's 13F filing for Q1 2023, filed 28 Apr 2023.